) connected to Main ibrutinib resistance in MCL cell traces. This observation was even further confirmed in 165 primary MCL samples in which 15% of your tumors that did not respond to ibrutinib therapy had mutations in TRAF3 Long-term activation of B-cell receptor (BCR) signaling by way of Bruton tyrosine https://zbigniewb075syd9.jasperwiki.com/user